![eva_riveira_edited.jpg](/sites/default/files/styles/1_1_small/public/imports/dest/drupal7_imatges/eva_riveira_edited.jpg?h=0ad36000&itok=QA7CrWJs)
Eva Riveira Muñoz
Eva Riveira Muñoz (b. 1977) obtained a degree in Biology from the University of Santiago de Compostela (USC). She then moved to Brussels (Belgium) to pursue a PhD degree, which she obtained from the Université Catholique de Louvain in 2007. Returning to Spain, she spent three years as a post-doc at the Centre for Genomic Regulation in Barcelona. In 2012 she moved to IrsiCaixa, where she is now working as a post-doc at the Virus-Host Interactions group, led by Ester Ballana.
Nucleotide-Binding Oligomerization Domain 1 (NOD1) Agonists Prevent SARS-CoV-2 Infection in Human Lung Epithelial Cells through Harnessing the Innate Immune Response.
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models.
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.